James Goodhand
A5024002886- Inflammatory Bowel Disease
- Microscopic Colitis
- SARS-CoV-2 and COVID-19 Research
- Biosimilars and Bioanalytical Methods
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Esophagitis
- COVID-19 Clinical Research Studies
- Chronic Lymphocytic Leukemia Research
- Autoimmune and Inflammatory Disorders Research
- Acute Lymphoblastic Leukemia research
- Health Systems, Economic Evaluations, Quality of Life
- Iron Metabolism and Disorders
- Pharmaceutical studies and practices
- Helicobacter pylori-related gastroenterology studies
- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Screening and Detection
- Clostridium difficile and Clostridium perfringens research
- Immunotherapy and Immune Responses
- Adolescent and Pediatric Healthcare
- Gastrointestinal motility and disorders
- Diverticular Disease and Complications
- Mycobacterium research and diagnosis
- Peripheral Neuropathies and Disorders
University of Exeter
2017-2024
Royal Devon & Exeter NHS Foundation Trust
2017-2024
St Mark's Hospital
2024
University Teaching Hospital
2023
Royal Devon and Exeter Hospital
2018-2021
University Gastroenterology
2016-2021
Phillips Exeter Academy
2021
PharmacoGenetics (China)
2020
University Medical Center Freiburg
2020
Dalhousie University
2020
Background & AimsAnti–tumor necrosis factor (anti-TNF) therapies are the most widely used biologic drugs for treating immune-mediated diseases, but repeated administration can induce formation of anti-drug antibodies. The ability to identify patients at increased risk development antibodies would facilitate selection therapy and use preventative strategies.MethodsWe performed a genome-wide association study variants associated with time in discovery cohort 1240 biologic-naïve Crohn's disease...
Objective Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more the population. We investigated whether patients with inflammatory bowel disease treated infliximab have attenuated serological responses to single vaccine. Design Antibody and seroconversion rates in infliximab-treated (n=865) were compared cohort vedolizumab (n=428), gut-selective anti-integrin α4β7 monoclonal antibody. Our primary outcome was anti-SARS-CoV-2 spike...
Anxiety and depression are common in patients with inflammatory bowel disease (IBD); however, the factors associated mood disorders ulcerative colitis (UC) Crohn's (CD) poorly defined.In all, 103 UC, 101 CD, 124 healthy controls completed Hospital Depression Scale (HADS). Disease activity was defined both from symptom scores UC endoscopically, CD by fecal calprotectin and/or serum C-reactive protein. Multivariate regression analyses were used to identify anxiety depression.In (HADS-A)...
Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following pneumococcal, influenza and viral hepatitis vaccination increase the risk of serious respiratory infections. We sought to determine whether infliximab-treated patients with IBD have attenuated serological responses SARS-CoV-2 infections.Antibody in participants treated infliximab were compared a reference cohort vedolizumab, gut-selective anti-integrin α4β7 monoclonal antibody that is not associated impaired...
IMPORTANCEUse of thiopurines may be limited by myelosuppression.TPMT pharmacogenetic testing identifies only 25% at-risk patients European ancestry.Among East Asian ancestry, NUDT15 variants are associated with thiopurine-induced myelosuppression (TIM).OBJECTIVE To identify genetic TIM among ancestry inflammatory bowel disease (IBD). DESIGN, SETTING, AND PARTICIPANTSCase-control study 491 affected and 679 thiopurine-tolerant unaffected who were recruited from 89 international sites between...
BackgroundThe effects that therapies for inflammatory bowel disease (IBD) have on immune responses to SARS-CoV-2 vaccination are not yet fully known. Therefore, we sought determine whether COVID-19 vaccine-induced antibody were altered in patients with IBD commonly used immunosuppressive drugs.MethodsIn this multicentre, prospective, case-control study (VIP), recruited adults treated one of six different treatment regimens (thiopurines, infliximab, a thiopurine plus ustekinumab, vedolizumab,...
Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection and impair protective immunity following pneumococcal influenza vaccination. Here we report SARS-CoV-2 vaccine-induced immune responses breakthrough infections in patients with inflammatory bowel disease, who are treated either anti-TNF antibody, infliximab, or vedolizumab targeting a gut-specific anti-integrin that does not systemic immunity. Geometric mean [SD] anti-S RBD antibody concentrations...
BackgroundWe sought to report the effectiveness of infliximab and adalimumab over first 3 years treatment define factors that predict anti-TNF failure strategies prevent or mitigate loss response.MethodsPersonalised Anti-TNF therapy in Crohn's disease (PANTS) is a UK-wide, multicentre, prospective observational cohort study reporting rates anti-TNF-naive patients with active luminal aged 6 older. At end year, sites were invited enrol participants still receiving drug into 2-year...
Children and adolescents with inflammatory bowel disease (IBD) are more likely to have Crohn's (CD) than ulcerative colitis (UC) their tends be extensive severe in adults. We hypothesized that the prevalence of anemia would therefore greater children adults attending IBD outpatient clinics.Using WHO age-adjusted definitions we assessed prevalence, severity, type, response treatment patients pediatric, adolescent, adult clinics at our hospital.The was 70% (41/59) children, 42% (24/54)...
Depression, like adverse events and psychological stress, can trigger relapse in inflammatory bowel disease (IBD); however, the effects of psychoactive drugs on course are unclear.Using retrospective electronic case note review, after exclusion five patients low-dose tricyclic antidepressants we compared IBD 29 (14 ulcerative colitis 15 Crohn's disease), during years before (year 1) 2) they were started an antidepressant for a concomitant mood disorder to that controls matched age, sex,...
Summary Background Few studies have reported the systematic use of exclusive enteral nutrition in perioperative setting. Aim To test hypothesis that provides a safe and effective bridge to surgery reduces post‐operative complications, adult patients with Crohn's disease requiring urgent for stricturing or penetrating complications. Methods Patients treated prior were each matched two control behaviour, type surgery, age at diagnosis duration. Data on phenotype, nutritional status, operative...
Significance Pharmacogenetics is a prototype of genomics-guided precision medicine. While there rapid expansion novel pharmacogenetic variants discovered by genome sequencing, the lack variant interpretation in scalable fashion formidable barrier this field. NUDT15 polymorphism major genetic cause for hematopoietic toxicity during thiopurine therapy. Motivated need to understand effects clinical actions, we developed massively parallel assay preemptively characterize 91.8% all possible...
Tofacitinib is a partially selective Janus kinase inhibitor approved for the treatment of refractory moderate to severe ulcerative colitis [UC]. We sought define effectiveness and adverse effects tofacitinib in real-world cohort.We conducted retrospective observational cohort study 134 patients with UC [64% male; median age 37 years [range 16-81]; 83% had previously received at least one biologic] treated from October 2018 2019 four UK centres. Disease activity was assessed using Simple...
BackgroundCOVID-19 vaccine-induced antibody responses are reduced in patients with inflammatory bowel disease (IBD) taking anti-TNF or tofacitinib after two vaccine doses. We sought to assess whether immunosuppressive treatments were associated and T-cell IBD a third dose.MethodsVIP was multicentre, prospective, case-control study done nine centres the UK. recruited immunosuppressed non-immunosuppressed healthy individuals. All participants aged 18 years older. The control group had no...
Patients with inflammatory bowel disease (IBD) treated anti-TNF therapy exhibit attenuated humoral immune responses to vaccination against SARS-CoV-2. The gut microbiota and its functional metabolic output, which are perturbed in IBD, play an important role shaping host responses. We explored whether the metabolome could explain variation anti-SARS-CoV-2 immunosuppressed IBD patients.Faecal serum samples were prospectively collected from infliximab-treated patients CLARITY-IBD study...
Background Upadacitinib is a Janus kinase inhibitor, which has recently been approved for treating Crohn’s disease. There are limited real-world studies on the outcomes of upadacitinib in Objective Our aim was to evaluate disease cohort. Methods We conducted retrospective, multicentre, cohort study over 2-year period across National Health Service (NHS) Lothian and Royal Devon University Healthcare NHS Foundation Trust. The primary outcome treatment persistence at week 24. Secondary...
BackgroundThe incidence of inflammatory bowel disease (IBD) is increasing among adolescents. In all, 25% patients are diagnosed before the age 16, when they traditionally transferred from pediatric to adult service.
Infliximab attenuates serological responses to SARS-CoV-2 infection. Whether this is a class effect, or if anti-tumour necrosis factor [anti-TNF] level influences responses, remains unknown.
Objective Antitumour necrosis factor (TNF) drugs impair serological responses following SARS-CoV-2 vaccination. We sought to assess if a third dose of messenger RNA (mRNA)-based vaccine substantially boosted anti-SARS-CoV-2 antibody and protective immunity in infliximab-treated patients with IBD. Design Third induced spike (anti-S) receptor-binding domain (RBD) responses, breakthrough infection, reinfection persistent oropharyngeal carriage IBD treated infliximab were compared reference...
Background Medication non-adherence seems to be a particular problem in younger patients with inflammatory bowel disease (IBD) and has negative impact on outcome. Aims To assess whether non-adherence, defined using thiopurine metabolite levels, is more common young adults attending transition clinic than IBD psychological co-morbidity contributing factor. We also determined the usefulness of Modified Morisky 8-item Adherence Scale (MMAS-8) detect non-adherence. Methods Seventy [51% (36)...
Background and aims: Few studies have specifically examined models of care in IBD. This survey was designed to help gather information from health professionals working IBD services on current models, their views how best reshape existing for worldwide.